MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,773.95
+0.66%
NASDAQ 100
$31,076.44
+0.87%
DOW JONES
$51,268.00
+0.18%
NASDAQ Composite
$27,477.31
+1.05%
RUSSELL 2000
$2,833.80
+0.66%
CBOE VIX
$15.52
+1.37%
Sector Heatmap
Technology+0.56%
Financials+0.73%
Healthcare+0.72%
Consumer Cycl+0.35%
Consumer Staples+0.63%
Energy+0.99%
Industrials+0.09%
Materials+1.31%
Real Estate-0.34%
Utilities+0.35%
Comm Services+1.17%
IKT — Inhibikase Therapeutics, Inc. Common Stock
NasdaqInhibikase Therapeutics, Inc. Common Stock
$2.00
+0.00(+0.00%)
- O
- 2.00
- H
- 2.03
- L
- 1.96
- V
- 407.33K
⏱️ End-of-day dataAs of Oct 5, 2026
IKT — Latest News & Headlines
4 StoriesTwo new hires receive options to buy up to 128,000 Inhibikase shares - Stock Titan
Two new hires receive options to buy up to 128,000 Inhibikase shares Stock Titan
Inhibikase Therapeutics (NASDAQ:IKT) Is In A Good Position To Deliver On Growth Plans - Simply Wall Street
Inhibikase Therapeutics (NASDAQ:IKT) Is In A Good Position To Deliver On Growth Plans Simply Wall Street
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Average Rating of "Buy" from Analysts - MarketBeat
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Average Rating of "Buy" from Analysts MarketBeat
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire